The recently published American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cardiovascular risk assessment provide equations to estimate the 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk in African Americans and non-Hispanic whites, include stroke as an adverse cardiovascular outcome, and emphasize shared decision making. The guidelines provide a valuable framework that can be adapted on the basis of clinical judgment and individual/institutional expertise. In this review, we provide a perspective on the new guidelines, highlighting what is new, what is controversial, and potential adaptations. We recommend obtaining family history of ASCVD at the time of estimating ASCVD risk and consideration of imaging to assess subclinical disease burden in patients at intermediate risk. In addition to the adjuncts for ASCVD risk estimation recommended in the guidelines, measures that may be useful in refining risk estimates include carotid ultrasonography, aortic pulse wave velocity, and serum lipoprotein(a) levels. Finally, we stress the need for research efforts to improve assessment of ASCVD risk given the suboptimal performance of available risk algorithms and suggest potential future directions in this regard. 
ª 2014 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2014;nn(n): [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] A ssessment of cardiovascular risk is a necessary first step to target therapy toward patients most likely to benefit. It has become evident that baseline atherosclerotic cardiovascular disease (ASCVD) risk is a better predictor of treatment benefit than the degree to which low-density lipoprotein cholesterol (LDL-C) is lowered. 1, 2 The recently published American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for cholesterol lowering 3 emphasize that the intensity of risk factor management should match the risk for adverse ASCVD events. In contrast, previous guidelines have favored achieving target LDL-C levels based on the magnitude of estimated cardiovascular risk. 4 The most recent ACC/AHA guidelines include a new ASCVD risk calculator for use in the clinical setting and address questions relevant to risk assessment using critical review of the available literature. The document includes a disclaimer that the recommendations are not a substitute for clinical judgment and that decisions about care must be individualized for each patient. The guidelines provide a valuable framework that can be adapted on the basis of clinical judgment and individual/ institutional expertise. In this review, we provide a perspective on the new guidelines for assessing risk of ASCVD events in adults without known disease, highlighting what is new, what is controversial, and potential future directions (Table 1) .
Preventive cardiologists from throughout the Mayo Foundation contributed to this document. A core writing group reviewed the guidelines and existing literature and made modifications based on foundation-wide expertise in cardiovascular risk assessment including imaging, circulating biomarkers, and genetic epidemiology. Input to the draft was provided by each author, and after several revisions, the draft was circulated to a Recommended Adjuncts to Refine Risk Estimates Additional variables were tested for inclusion in the model if they were available in the databases and could be evaluated on the basis of at least 10 years of follow-up, using the framework suggested by Hlatky et al. 20 These variables included diastolic blood pressure, family history of ASCVD, moderate or severe chronic kidney disease (defined as an estimated glomerular filtration rate of <60 mL/ min per 1.73 m 2 ), 21 and body mass index (continuous or categorical). None of these variables significantly improved prediction of 10-year ASCVD events when added to the final base models. The guidelines recommend 4 markers that may be considered by clinicians and patients if uncertainty remains after calculating the 10-year ASCVD riskd family history, high-sensitivity C-reactive protein (hs-CRP), ankle-brachial index (ABI), and coronary artery calcium (CAC) score.
Focus on Hard ASCVD Events
Compared with earlier guidelines, the new risk assessment guidelines attempt to take into account that atherosclerosis is a chronic disease that affects multiple vascular beds. Risk is estimated for "hard" ASCVD events including stroke, myocardial infarction, and death due to stroke or myocardial infarction. "Soft" end points such as those that might be influenced by physician preferences (eg, revascularization
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n The availability of race-and sex-specific equations for estimating 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk, inclusion of stroke as an adverse cardiovascular outcome, and the emphasis on shared decision making are strengths of the new American College of Cardiology/American Heart Association guidelines for ASCVD risk assessment.
n The guidelines recommend 4 measures that may be considered by clinicians and patients as adjuncts for refining risk estimatesdfamily history of ASCVD, high-sensitivity C-reactive protein, ankle-brachial index, and coronary artery calcium scoring.
n Additional measures that may be useful in risk estimation include carotid ultrasound, aortic pulse wave velocity, and circulating levels of lipoprotein(a).
n Because of the suboptimal performance of available ASCVD risk algorithms, research efforts to improve risk assessment in asymptomatic adults should be intensified.
procedures) and end points that are often difficult to ascertain reliably (eg, angina and heart failure), were not included.
Recommendations for Estimating Lifetime Risk
The ACC/AHA guidelines have a primary focus on 10-year risk of ASCVD events and a secondary focus on assessing lifetime risk for adults 20 to 59
years old who are not at high short-term risk.
Beginning at age 40, formal estimation of the 10-year risk for ASCVD is recommended. Longterm or lifetime risk estimation is recommended for all persons who are 20 to 39 years of age and for those 40 to 59 years old who are at low 10-year risk (<7.5%). At present, there is insufficient evidence for initiating pharmacological therapy on the basis of lifetime risk assessment, 24 Asian American, 25 and American Indian populations. For example, there is considerable heterogeneity in ASCVD risk among Asian populations, and those from the Indian subcontinent are considered to be at higher risk. 25 Given the absence of data, the guidelines recommend the use of equations derived from non-Hispanic whites in these ethnic groups, cautioning that the resulting risk estimates may be less accurate.
Variable Performance of the ASCVD Risk Calculator in Other Cohorts
Subsequent to the publication of the guidelines, investigators have tested the performance of the ASCVD calculator in several cohorts. In 2 large cohorts of nurses and physicians, respectively, the ASCVD risk calculator performed suboptimally in terms of accuracy and discrimination, 26 overestimating risk by up to 100%. However, individuals in these cohorts were likely to engage 
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in healthy lifestyles and also to be taking lipidand blood pressureelowering medications. In a randomly sampled contemporary cohort of 30,239 adults from geographically diverse regions of the United States, 10,997 were eligible for statin drugs on the basis of the recent guidelines; observed and 5-year ASCVD risks predicted using the ASCVD risk calculator were similar, with moderate to good discrimination. 27 Kavousi et al 28 applied the ACC/AHA, the ATP-III, 4 and the European Society of Cardiology 29 guidelines to a Dutch cohort of 4854 participants aged 55 years or older who were recruited between 1997 and 2001. The risk equations provided modest discrimination; for example, in men, using the ASCVD risk calculator, the C statistic was 0.67 for hard ASCVD events, 0.67 for hard CHD events, and 0.76 for ASCVD mortality. These studies highlight that the ASCVD risk equations may need to be recalibrated when used in non-US populations as well as the need for additional validation of the ASCVD risk equations.
Adjunctive Measures for Risk Stratification
Although an LDL-C level 160 to 189 mg/dL and a relatively high lifetime ASCVD risk can help in deciding whether to start statin therapy, 4 measures are recommended by the guidelines for use when there is uncertainty about ASCVD risk even after the risk calculator is used ( Table 2 ). The following caveats should be considered when using these adjunctive measures for cardiovascular risk estimation.
Family history. Family history is considered a "free genomic tool" 30 but was not included in the risk equations because definitions varied among studies and information was often Ankle-Brachial Index. Although noninvasive and inexpensive, the ABI is not a sensitive measure of lower extremity arterial disease. Sensitivity can be increased by measuring ABIs after exercise, but this requires a treadmill exercise test with electrocardiographic monitoring. Furthermore, the ABI is lower in women and African Americans, 32 and sex-and race-specific cutoffs for defining an abnormal ABI remain to be established. In patients with diabetes, the ABI can be elevated because of medial arterial calcification. Finally, the ABI may be useful only in older persons, most of whom would already have been identified as being at higher risk by the ASCVD risk calculator.
High-Sensitivity C-Reactive Protein. The incremental predictive value of hs-CRP remains unclear. [33] [34] [35] [36] [37] [38] [39] Also controversial is whether baseline hs-CRP levels predict response to statin therapy. 40 Levels differ by race and sex. 41 In the clinical setting, elevations in hs-CRP often represent the presence of central obesity, metabolic syndrome, estrogen use, recent infection, or trauma. 42 The ordering physician should be aware of these caveats and interpret levels accordingly.
Threshold for Using Statins
The guidelines recommend statin treatment when the 10-year ASCVD risk is 7.5% or higher and consideration of therapy in those with a 10-year risk between 5.0% and less than 7.5%. 3 The cut points were based on randomized controlled trials of statins that revealed reduction in adverse ASCVD outcomes at these levels of risk. 1 In the analysis by Kavousi et al, 28 the ACC/AHA guidelines would recommend statins for nearly all men and two-thirds of women older than 55 years, proportions exceeding those based on the ATP-III or European guidelines. When such large proportions meet the treatment threshold, risk estimation becomes redundant, and a "polypill" or universal treatment strategy comes into play. 43 Certainly in making decisions on potentially lifelong therapy in mostly asymptomatic individuals, it is important to take into account patient choices. 44 One option may be to expand the intermediate risk category to 5% to 10% or even 5% to 15% and use adjunctive measures to further refine and individualize risk estimates to facilitate shared decision making regarding statin use. 45 Such an approach would need further investigation to determine optimal screening algorithms to minimize cost and how to use the results of adjunctive testing to refine risk estimates downward (avoid treatment) or upward (and make a stronger case for treatment).
Using Information From Adjunctive Tests to Modify 10-Year ASCVD Risk Adjunctive tests might improve risk assessment in individuals at intermediate 10-year ASCVD risk and in those who are at low risk (<5%) but have very high levels of a single risk factor, a strong family history of ASCVD, or chronic inflammatory disease (see 2 illustrative case studies in Figure 2) . Because of lack of data, no specific recommendations can be made on how these markers should be used to modify risk estimates. One proposed option is to replace the chronological age in the ASCVD risk calculator with the "vascular age" derived from imaging results. 46 Another option is to multiply the baseline ASCVD 10-year risk by the hazard ratio (HR) associated with an abnormal result; for example, having a CAC score greater than the 75th percentile for age and sex could double the risk independent of conventional risk factors, so the 10-year risk could be multiplied by 2. The validity of this approach is uncertain because it does not take into account the prevalence of the abnormal risk marker. 47 Finally, whether to downgrade a patient's risk estimated from the ASCVD calculator on the basis of results from adjunctive testing is another area of controversy.
Special Populations
There is insufficient evidence to guide management of certain patient populations who may be at increased risk of adverse cardiovascular outcomes. The additive risk of these conditions independent of conventional risk factors is uncertain. These conditions include systemic inflammatory diseases, 48 a history of gestational diabetes or hypertensive disorders of pregnancy inluding preeclampsia, 49 chronic kidney disease, 50 and human immunodeficiency virus infection. 51 Imaging studies to assess subclinical disease burden may be useful in these settings to better define ASCVD risk.
USE OF ADJUNCTIVE MEASURES TO REFINE ESTIMATES OF ASCVD RISK
We suggest the following adaptation of the ACC/AHA guidelines for the use of adjunctive tests to refine ASCVD risk estimates.
Family History
A family history of early-onset ASCVD (defined as occurrence of an ASCVD event in a firstdegree male relative before age 55 years or in a first-degree female relative before age 65 years) should be sought from every patient who presents for cardiovascular screening. 30, [52] [53] [54] We recommend obtaining a family history concurrent with estimating risk using the ASCVD calculator, rather than later as an adjunctive measure. The presence of a family history of ASCVD is likely to be an important factor in shared decision making regarding lifestyle changes and statin use and also provides an opportunity to detect additional individuals in a family who may be at risk. We recognize the need for additional studies to estimate more precisely the relative risk that results from the presence of a family history of ASCVD. In the absence of robust relative risk estimates for the presence of family history, clinical judgment could be utilized in deciding how much to "adjust" the risk estimated from the ASCVD equation.
Adjunctive Testing
We agree that CAC scoring can be used selectively to aid decision making in situations in which the clinician is uncertain about the patient's short-term and long-term cardiovascular risk. We recommend against the use of CAC Case 1 A 47-year-old woman undergoing a general medical evaluation is concerned about her atherosclerotic cardiovascular disease (ASCVD) risk given her family history (her mother had ischemic stroke at age 53 years). The patient is asymptomatic and does not have diabetes or hypertension but smokes 5 cigarettes a day. She exercises 2 to 3 times a week on an elliptical machine. Her lipid profile includes a total cholesterol level of 198 mg/dL (to convert to mmol/L, multiply by 0.0259), high-density lipoprotein cholesterol level of 48 mg/dL (to convert to mmol/L, multiply by 0.0259), triglyceride level of 110 mg/dL (to convert to mmol/L, multiply by 0.0113), and calculated low-density lipoprotein level of 128 mg/dL (to convert to mmol/L, multiply by 0.0259). On examination, the patient's blood pressure is 128/76 mm Hg, and cardiovascular examination findings are unremarkable. Her 10-year ASCVD risk is estimated at 4.1%, but given her family history of stroke, her physician orders carotid ultrasonography to determine the intima-media thickness and presence or absence of plaque. Her common carotid intima-media thickness is greater than the 75th percentile for her age and sex, and she also has focal intimal thickening in both carotid bulbs. After a discussion of her overall risk factor profile, family history, carotid ultrasonographic findings, and the potential benefit, cost, and adverse effects of statins, she opts for moderateintensity statin therapy. She is also counseled to quit smoking.
Case 2
A 56-year-old African American man who is an executive is undergoing general medical evaluation including screening for cardiovascular disease. He is asymptomatic and exercises 4 times a week, 45 minutes each time. He is a nonsmoker and has no hypertension, diabetes, or family history of ASCVD. His cardiovascular examination yields normal findings. His blood pressure is 126/80 mm Hg. His lipid profile includes a total cholesterol level of 165 mg/dL, high-density lipoprotein cholesterol level of 60 mg/dL, triglyceride level of 125 mg/dL, and low-density lipoprotein cholesterol level of 80 mg/dL. His 10-year ASCVD risk is estimated at 6.1%. After a discussion with his preventive cardiologist, the patient remains uncertain whether he wants to take a statin and opts for additional testing. Computed tomography is performed to detect coronary calcium and reveals no evidence of calcified plaque. The patient, in consultation with his preventive cardiologist, decides to withhold statin treatment and to continue his regular exercise program and a low saturated fat diet. scores to monitor patients longitudinally, given the unclear implications of change in CAC scores over time and the potential for additional radiation exposure. The potential for missing "soft plaque" in younger individuals (<50 years) should be recognized. Measurement of ABI could be considered for risk stratification selectively, for example in individuals with a family history of early-onset peripheral arterial disease. High-sensitivity C-reactive protein testing may be considered for refining risk estimates, recognizing the limitations stated previously. We recommend that the following additional markers also be considered as adjuncts to risk stratification (Table 3) .
Carotid Ultrasonography. Carotid ultrasonography is a relatively easily available, noninvasive imaging modality that does not involve radiation exposure. The ACC/AHA guidelines recommend against the use of carotid intima-media thickness (IMT) measurement in routine clinical practice for ASCVD risk assessment on the basis of a published meta-analysis that found that common carotid artery (CCA) IMT added only modestly to risk prediction based on traditional risk factors. 55 This meta-analysis included 14 population-based cohorts and 45,828 patients, and found that the addition of CCA IMT was associated with modest improvement in predicting 10-year risk of incident myocardial infarction. 55 The net reclassification index improvement with the addition of CCA IMT was 3.6% for those at intermediate risk. However, the meta-analysis did not study the predictive utility of carotid plaque detection.
Carotid plaque, a manifestation of atherosclerosis, typically forms in the carotid bifurcation and internal carotid artery. Intima-media thickness is measured in the CCA where plaque formation is uncommon. Thus, the two are independent predictors of future ASCVD events, and in observational studies, combining plaque and CCA IMT measurements performed better than CCA IMT measurement alone. A meta-analysis of 11 population-based studies that included 54,336 patients found that carotid plaque, when compared with carotid IMT, was more strongly associated with incident CHD. 56 In the ARIC study of 13,145 participants with a mean follow-up of 15.1 years, using both plaque and CCA IMT measurements led to more accurate risk stratification of 23% of participants when added to conventional risk factors. 57 The consensus statement for use of carotid ultrasonography from the American Society of Echocardiography 58 recommends screening for the presence of plaque as well as measurement of CCA IMT.
The ACC/AHA guidelines also voiced concern regarding measurement quality. Carotid ultrasonography, however, has been used in the research and clinical settings for nearly 4 decades, and considerable expertise has developed over time. The measurement of CCA IMT has high reproducibility, and consensus recommendations for use of carotid ultrasonography have been available since 2008. 59, 60 The use of established protocols and edge-detection methods for CCA IMT reduces the potential for variability and the concerns related to standardization. Furthermore, appropriate use criteria for carotid ultrasonography are also in place. 61 We therefore believe it is reasonable to consider selective use of carotid ultrasonography for risk stratification, employing plaque screening and measurement of CCA IMT.
Aortic Pulse Wave Velocity. Noninvasive assessment of arterial properties remains limited to blood pressure even though newer techniques such as ultrasonography and tonometry allow measurement of several aspects of arterial function that are relevant for ASCVD risk estimation. 62 Aortic pulse wave velocity (aPWV), the current gold standard for noninvasive measurement of arterial stiffness, is relatively easily measured by arterial tonometry and is predictive of ASCVD outcomes independent of conventional risk factors. 62 A recent meta-analysis 63 illustrated the incremental and independent predictive value of aPWV for predicting adverse ASCVD outcomes. In 17,635 individuals from 16 studies, of whom 1785 (10%) had an ASCVD event, the pooled age-and sex-adjusted HRs per 1-SD increase change in log aPWV were 1. The European Society of Hypertension recommends measurement of aPWV for assessment of target organ damage in hypertensive individuals. 64 Knowledge of aPWV may also guide therapy; treatment of hypertension reduces arterial stiffness by reducing distending pressure, although drugs such as angiotensin receptor blockers may act additionally on intrinsic vascular wall properties to reduce stiffness. 65 Aerobic exercise reduces arterial stiffness, and individuals with increased arterial stiffness should be motivated to start an exercise program. 66 Lipoprotein(a) Levels. There is considerable evidence that elevated levels of lipoprotein(a) (Lp[a]) are associated with increased risk of CHD. In contrast to several novel risk factors (including hs-CRP), Lp(a) has a causal role in ASCVD, as illustrated in a mendelian randomization study that found that genetic variants that increase Lp(a) levels are associated with adverse ASCVD events. 67 Elevated levels appear to contribute to familial clustering of CHD 68 and provide incremental information for risk estimation. 69 Lipoprotein(a) levels are heritable and do not change considerably over the course of a lifetime. A one-time measurement of Lp(a) should be considered when there is uncertainty in the estimates of 10-year ASCVD risk, particularly in those with a family history of ASCVD. No specific therapy for reduction of Lp(a) levels is available, but lowering of LDL-C level may blunt the risk from elevated Lp(a). 70 Research is ongoing to identify drugs that selectively lower Lp(a) levels.
FUTURE DIRECTIONS
Considerable progress has been made in identifying risk factors for ASCVD and developing multivariate risk prediction equations. Perhaps the most important limitation of risk calculators, including the new ASCVD risk calculator, is that they provide risk estimates for populations rather than individuals, are probabilistic, and tend to be only modestly accurate, with considerable variability across various populations. Thus, only 40% to 50% of individuals who experience cardiovascular events are considered high-risk candidates by most currently used risk profiles. 71 In the MESA (Multi-Ethic Study of Atherosclerosis) study, almost 60% of the events (123 of 209) occurred among individuals who were not classified as being at high risk by either traditional risk factors or CAC score. 71 Further research is needed to identify newer modalities to refine ASCVD risk. As more has been learned about the biology of atherosclerosis, 2 main paradigms important for ASCVD risk assessment have become apparent: (1) the complexity of ASCVD necessitates a multimodal and multimarker approach 72 and (2) periodic assessment is needed given the dynamic nature of plaque activity and ASCVD risk. Table 4 summarizes potential future research directions in refining estimates in asymptomatic individuals. The following sections briefly discuss the potential use of imaging multiple markers, genetic susceptibility variants, and newer statistical techniques in this regard.
Imaging and Physiologic Assessment
The evidence base needs to be expanded to facilitate informed use of available noninvasive modalities for imaging and assessment of arterial function for early detection of disease and to assess subclinical plaque burden. Although the concept of "vulnerable plaque" has existed for many years, 73, 74 there is a need for noninvasive imaging modalities to identify vulnerable plaque and characterize temporal changes in plaque activity. Cost, availability, and radiation exposure are additional factors that require investigation to establish best practices for the use of imaging. Two risk assessment methods could also be considereddone that is low cost and widely applicable but with reduced accuracy and a second that adds cost and accuracy and may be used in patients in whom the need for intervention is less clear.
Multiple Markers
Given the complexity of ASCVD, it is unlikely that a single marker will provide sufficiently incremental predictive information about risk, and many novel risk factors have been proposed for assessing ASCVD risk. 72, 75 Multiple etiologic pathways lead to the development of ASCVD and to adverse cardiovascular events. Use of multiple markers will be necessary to meaningfully improve the accuracy of risk estimates. [76] [77] [78] Genetic Susceptibility Variants Nearly 46 genetic susceptibility variants for CHD have been identified, 79 and individuals with an excess of these variants may be at increased risk for CHD. 80 Although the variants have modest effect sizes, most are not associated with conventional risk factors and therefore provide an orthogonal means of risk assessment, in contrast to several existing biomarkers such as hs-CRP whose incremental predictive utility is diminished because of its correlation with factors such as obesity, diabetes, and hypertension. In several cohorts with available information on incident adverse events, genetic risk scores calculated on the basis of these variants have been found to be independently predictive of adverse cardiovascular events. 81 At Mayo Clinic in Rochester, Minnesota, a pilot clinical trial funded by the National Human Genome Research Institute, the Myocardial Infarction Genes (MI-GENES) study, is under way to test the concept of using genomic information to refine assessment of CHD risk. 82 
New Statistical Approaches
Recently, new statistical techniques (including net reclassification improvement and integrative discrimination index) have been adopted to examine the utility of novel biomarkers in different populations and patient subgroups. 83, 84 Continuing work is needed to develop new statistical models to account for multiple markers, interactive effects of risk factors, and their different effects at different ages.
CONCLUSION
The availability of race-and sex-specific equations for estimating 10-year and lifetime ASCVD risk, inclusion of stroke as an adverse cardiovascular Overall, we agree with the general principles of the guidelines and suggest certain adaptations for use in the clinical setting. We recommend eliciting a family history of ASCVD at the time the risk calculator is used, followed by consideration of the use of CAC score or carotid ultrasonography to assess for subclinical disease burden. Additional measures that may be useful in risk estimation include aPWV and circulating levels of Lp(a). Finally, the suboptimal performance of available ASCVD risk algorithms needs to be acknowledged, and research efforts to improve risk assessment in asymptomatic adults should to be intensified.
Abbreviations and Acronyms: ABI = ankle-brachial index; ACC = American College of Cardiology; AHA = American Heart Association; aPWV = aortic pulse wave velocity; ASCVD = atherosclerotic cardiovascular disease; ATP-III = Adult Treatment Panel III; CAC = coronary artery calcium; CCA = common carotid artery; CHD = coronary heart disease; HR = hazard ratio; hs-CRP = high-sensitivity C-reactive protein; IMT = intima-media thickness; LDL-C = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a)
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